Gammagard Liquid Injection, Solution
NDC Package 0944-2700-07
Package Information
Gammagard Liquid (immune globulin infusion (human)) injection is a medication used in people with a certain type of weakened immune system (primary immune deficiency) to strengthen it and to lower the risk of infection. This formulation utilizes a injection, solution delivery system. Marketed by Takeda Pharmaceuticals America, Inc., this product is identified by NDC 0944-2700 and is authorized under FDA application BLA125105.
Identification & Billing
- RxCUI: 1809414 - immunoglobulin G, human 10 % in 50 ML Injection
- RxCUI: 1809414 - 50 ML immunoglobulin G, human 100 MG/ML Injection
- RxCUI: 1809414 - immunoglobulin G, human 10 % per 50 ML Injection
- RxCUI: 1809414 - immunoglobulin G, human 5 GM per 50 ML Injection
- RxCUI: 1809421 - immunoglobulin G, human 10 % in 100 ML Injection
Clinical Specifications
- Intravenous - Administration within or into a vein or veins.
- Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
Regulatory & Marketing
Hierarchy Structure
- 0944 - Takeda Pharmaceuticals America, Inc.
- 0944-2700 - Gammagard Liquid
- 0944-2700-07 - 1 BOTTLE, GLASS in 1 CARTON / 300 mL in 1 BOTTLE, GLASS (0944-2700-13)
- 0944-2700 - Gammagard Liquid
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Billing & HCPCS Mapping
To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.
Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (0944-2700). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0944-2700-07 identifies a specific commercial package of 1 bottle, glass in 1 carton / 300 ml in 1 bottle, glass (0944-2700-13) of Gammagard Liquid, a plasma derivative labeled by Takeda Pharmaceuticals America, Inc.. This injection, solution is formulated for intravenous; subcutaneous use and contains human immunoglobulin g as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Takeda Pharmaceuticals America, Inc. on April 27, 2005. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is used in people with a certain type of weakened immune system (primary immune deficiency) to strengthen it and to lower the risk of infection. This medication is made from human blood that has a high level of antibodies which help fight infections. This product is also used to increase the number of certain blood cells (platelets) in people with a certain blood disorder (idiopathic thrombocytopenic purpura-ITP). Platelets are needed to stop bleeding and to form normal blood clots. In addition, this medication is used to treat a certain nerve disorder (chronic inflammatory demyelinating polyneuropathy-CIDP). This disorder causes weakness and numbness/tingling/pain in the arms and legs. This medication helps to improve these symptoms and prevents relapse.
How is this Takeda Pharmaceuticals America, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00944270007. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.
